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Abstract 
The inhibition of tumor angiogenesis has become a compelling approach in the 
development of anticancer drugs. In the present study, topological models were 
developed through decision tree and moving average analysis using a data set 
comprising 42 analogues of 3-aminoindazoles. A total of 22 descriptors 
(distance based, adjacency based, pendenticity and distance-cum-adjacency 
based) were used. The values of all 22 topological indices for each analogue in 
the dataset were computed using an in-house computer program. A decision 
tree was constructed for the receptor tyrosine kinase KDR (kinase insert domain 
receptor) inhibitory activity to determine the importance of topological indices. 
The decision tree learned the information from the input data with an accuracy 
of 88%. Three independent topological models were also developed for 
prediction of receptor tyrosine kinase inhibitory (KDR) activity using moving 
average analysis. The models developed were also found to be sensitive 
towards the prediction of other receptor tyrosine kinases i.e. FLT3 (fms-like 
tyrosine kinase-3) and cKIT inhibitory activity. The accuracy of classification of 
single index based models using moving average analysis was found to be 
88%. The performance of models was assessed by calculating precision, 
sensitivity, overall accuracy and Mathew’s correlation coefficient (MCC). The 
significance of the models was also assessed by intercorrelation analysis.  
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Introduction 
Cancer is a leading cause of death worldwide and accounted for 7.9 million deaths 
(around 13% of all deaths) in 2007. Moreover, the deaths resulting from cancer are 
expected to rise continuously with an estimated 12 million deaths in 2030 [1]. Cancer is 
thought to reflect a multistep process, resulting from an accumulation of inherited, acquired 
or both defects in genes involved in the positive or negative regulation of cell proliferation 
and survival. Activation or inactivation of just four or five different genes may be required 
for the development of clinically recognizable human cancer [2]. Despite advances in 
diagnosis and treatment, overall survival of patients still remains poor. Surgery, 
chemotherapy, radiotherapy, and endocrine therapy have been the standard options 
available for treatment of cancer patients. This has improved survival in several types of 
solid tumors, but treatment-related toxicity and emergence of drug resistance have been 
the major causes of morbidity and mortality [3]. Consequently, there is an urgent need to 
develop newer more effective therapies to improve patient outcomes. Blood is essential for 
solid tumors to manage nutritional supplies and waste removal to manage the tumor 
growth and metastasis. Angiogenesis is a process in which new blood vessels are formed 
from pre-existing vasculatures [4]. It has been reported that the angiogenesis is a rate 
limiting step in tumor development. Tumors that lack adequate vasculature become 
necrotic or apoptotic and don’t grow beyond a limited size [5,  6]. Inhibition of tumor 
angiogenesis has become a compelling approach in development of anticancer agents 
[7, 8]. Vascular endothelial growth factor (VEGF) is the primary endothelial cell specific 
angiogenic factor [9]. VEGF activity is mediated by three higher affinity receptors 
belonging to the class-V subfamily of receptor tyrosine kinases (RTKs). These are widely 
known for regulating angiogenesis, vasculogenesis, and lymphangiogenesis. The VEGFR 
family includes VEGFR-I/FLT-1 (fms-like tyrosine kinase-I), VEGFR-2/FLK-I (fetal liver 
kinase-I)/KDR (kinase inert domain containing receptor) and VEGFR-3/FLT-4 (fms-like 
tyrosine kinase-4). VEGFR-I is required for endothelial organization during vascular 
development while VEGFR-2 is required for formation of blood islands and also 
hematopoiesis [3, 5]. VEGFR-3 plays a significant role in VEGF-C and VEGF-D-mediated 
lymphangiogenesis. Over activation of KDR by VEGFs has been linked to progression of 
variety of human cancers. VEGF mediated KDR signaling induces a series of endothelial 
responses such as proliferation, migration and survival which ultimately leads to new 
vessel formation and maturation [10–13]. The immature tumor vasculature lacking a close 
association with pericytes appears to be most susceptible to inhibition of VEGFR signaling 
[14] and resistance to continued inhibition of VEGFR signalling has been reported [15]. 
Evidence increasingly points to a key role for PDGFR (platelet derived growth factor 
receptor tyrosine kinsases), located on the pericytes in the tumour stroma, in angiogenesis 
and vessel maturation and highlights its potential as a therapeutic target [16]. PDGFR is 
class III subfamily of RTKs including five receptors i.e. PDGFR-α, PDGFR-β, CSF-IR 
(colony stimulating factor 1 receptor), cKIT and FLT3 involved in cellular growth, 
differentiation, cytokine vascular regulation, gliomas and leukemia [3, 17]. FLT3 is shown 
to be commonly overexpressed in most B lineage acute lymphocytic leukemia (ALL), acute 
myeloid leukemias (AMLs) and chronic myeloid leukemias (CML) [18]. Preclinical studies   Models for the Prediction of Receptor Tyrosine Kinase Inhibitory Activity of Substituted …  241 
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have already shown the benefits of combining VEGFR and PDGFR inhibition with respect 
to tumour response [19]. Due to vital role that RTKs play in tumor angiogenesis, inhibition 
of these may prove to be an effective therapeutic intervention and potential inhibitors can 
be explored [2, 3]. 
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Fig. 1.  Basic structures of 3-aminoindazole analogues [34] 
The drug research and development is comprehensive, expensive, time-consuming and 
full of risk [20]. The traditional approach of drug discovery involves target identification, 
validation, lead search and optimization followed by clinical development phases [21]. The 
experimental search for better activities in drug discovery is commonly carried out in the 
laboratory by optimizing the structure–activity relationship (SAR) of the functional groups 
present in a leading structure in terms of their biological endpoint. However, an interesting 
alternative to this trial-error based procedure that constitutes an active field in complex 
biochemical phenomena are the analysis through Quantitative Structure–
Activity/Property/Toxicity Relationships (QSAR/QSPR/QSTR) [22]. Quantitative structure-
activity relationship (QSAR) represents an attempt to correlate structure descriptors of 
compounds with their biological activity [23, 24]. An important aspect of this method is the 
use of good structural descriptors that represent the molecular features responsible for the 
relevant biological activity [25]. The chemical graph theory is largely applied to the 
quantitative characterization of molecular structures for predicting physicochemical, 242  M. Gupta, H. Dureja and A. K. Madan:   
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pharmacological and toxicological properties using graph theoretical invariants 
[26, 27].The graph theoretical invariants have been termed as topological indices [28, 29]. 
The computation of TI is very swift and the TIs have the advantage of being true structural 
Invariants, which means that their values are independent of molecular conformations [25]. 
In last few decades, the topological indices have emerged as powerful tools for predicting 
biological activity of molecules, and lead identification forming an integral part of new 
molecular research [30–33]. In the present study, relationship of topological descriptors 
with KDR inhibitory activities of 3-aminoindazoles has been investigated using decision 
tree and moving average analysis. The proposed models were also evaluated for the 
prediction of FLT3 and cKIT inhibitory activities. 
Methodology 
Dataset 
A dataset comprising of 42 analogues of substituted 3-aminoindazoles [34] was selected 
for the present investigations. The basic structure for these analogues is depicted in Fig. 1. 
and various substituents are enlisted in Tab. 1.  
Kinase enzymatic assays of al the 42 analogues were preformed by Dai et al. [34] utilizing 
the homogeneous time-resolved fluorescence (HTRF) protocol. Peptide substrate at 4 µM, 
1 mM ATP, enzyme and inhibitors (3.2 nM to 50 µM) were incubated for 1 hour at ambient 
temperature in 50mM NaOH (pH 7.5), 10mM MgCl2, 2mM MnCl2, 2.5 mM DTT, 0.1 mM 
orthovandate and 0.01% bovine serum albumin. The reactions were stopped with 0.5 M 
EDTA and then 75 µL buffer containing detecting agents (streptividine-allphycocyanin and 
PT66 antibody europium cryptate) was added. The plates were read from 1to 4 hour for 
time-resolved fluorescence. The inhibition was calculated using control and background 
reading. Each IC50 determination was preformed with seven concentrations and each 
assay point was reportedly determined in duplicate [34]. 
Subsequently, based on the results of KDR enzymatic assay, the potent inhibitors were 
reportedly characterized by cellular assay using 3T3 – murine fibroblasts cells [34]. 
The in vivo activity of compounds with potent cellular activity was also reportedly carried 
out using an estradiol-induced mouse uterine edema (UE) model. The said assay served 
as a valuable tool for a rapid and preliminary evaluation of KDR inhibitor’s oral activity. 
The dataset comprised of variable degree of activities. Compounds having reported IC50 
values of ≤ 10 nM were considered to be active while those possessing IC50 values >10 
nM were treated to be inactive for the purpose of present study. 
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Tab. 1.   Relationship between topological indices and KDR inhibitory activity  
KDR inhibitory activity
Predicted using
MAA models 
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1 A 
NH2
 
− 86.79  494.18  4.11 −  −  −  − 
2 B 
O
 
− 123.29  1674.22 2.02 −  −  −  − 
3 B 
S
O
O
 
− 164.96  2093.78 2.15 −  −  −  − 
4 B 
O
N
H
 
− 129.46  1949.52 1.76 −  −  −  − 
5 C 
 
− 135.45  2172.95 1.81 −  −  − + 
6 C 
S  
− 135.46  1750.1  1.98 −  −  −  − 
7 C 
 
− 125.46  1729.09 1.98 −  −  −  − 
8 C 
 
− 123.29  1674.22 2.02 −  −  −  − 
9 D  2−F  − 136.20  2160.53 1.82 −  −  −  − 
10 D  3−F  − 137.78  2180.53 1.81 −  −  −  − 
11 D  4−F  − 137.79  2200.53 1.58 −  −  −  − 
12 D  2−Me  − 134.45  2152.95 1.82 −  −  −  − 
13 D  4−Me  − 135.46  2192.95 1.58 −  −  −  − 
14 D  3−Et  − 139.46  2423.38 1.62 +  +  +  + 
15 D  3−Cl  − 143.29  2198.40 1.81 +  −  − + 
16 D  3−Br  − 158.12  2246.62 1.81 −  −  −  − 
17 D  3−CF3  − 152.70  2955.6  1.72 −  − +  + 
18 D  3−OH  − 136.79  2177.28 1.81 −  −  −  − 
19 D  2−F−5−Me  − 141.20  2389.25 1.87 +  +  − + 
20 D  3−Me−4−F  − 144.37  2427.25 1.63 +  +  +  + 
21 D  3−F−4−Me  − 144.37  2427.25 1.63 +  +  +  − 
22 D  2−F−5−CF3  − 153.70  3191.65 1.78 −  −  −  − 
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Tab. 1.   (Cont.) 
KDR inhibitory activity
Predicted using
MAA models 
Cpd. 
No. 
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23 E  3−Me  −Me 141.62  2383.54 1.73 +  +  + + 
24 E  3−Me  OH  147.1 2635.78 1.67 −  − +  − 
25 E  3−Me  N O 144.63 2391.41 1.73 +  +  +  + 
26 E  2−F−5−Me  O   170.90 2460.04 1.73 − +  +  + 
27 F  3−Me  −Me 165.41  3909.63 1.43 −  −  −  − 
28 F  3−Me  −OMe 173.57  4669.82 1.39 −  −  −  − 
29 F  3−Me  −F 179.73  4664.31 1.41 −  −  −  − 
30 F  3−Me  −Br 190.45  5587.48 1.28 −  −  −  − 
31 F  3−Me 
O
N 192.51 5554.98 1.36 −  −  −  − 
32 F  3−Me  O
N
 
161.78 3572.18 1.42 −  −  −  − 
33 F  3−Me  O
N
 
175.23 4126.54 1.5  −  −  −  − 
34 F  3−Me  O
N
 
173.85 4123.64 1.5  −  −  −  − 
35 F  3−Me 
O
N
O
 
141.96 2409.05 1.54 +  +  −  − 
36 F  3−Me  O   150.18 2924.31 1.42 −  −  −  − 
37 F  3−Me  NO 179.93 4595.26 1.28 −  −  −  − 
38 F  3−Me  NN161.09 3501.97 1.54 −  −  −  − 
39 F  3−Cl  O   169.62 3602.53 1.42 −  −  −  − 
40 F  2−F−5−Me  O   167.53 3873.60 1.45 −  −  −  − 
41 F  2−F−5−Me  O
N
 
179.32 5030.37 1.41 −  −  −  − 
42 F  2−F−5−Me  O
N
 
192.26 5466.49 1.37 −  −  −  − 
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Topostructural and topochemical indices 
Twelve topostructural and ten topochemical indices [30, 35–55] used for the present study 
are presented in Tab. 2. The distance based topological descriptor (Wiener index, Balaban 
index), adjacency based descriptors (Zagreb group parameter, M1  and M2,  molecular 
connectivity index) and distance cum adjacency based topological descriptors (eccentric 
adjacency index, augmented eccentric connectivity index, superadjacency index, eccentric 
connectivity index, connective eccentric index, superaugmented eccentric connectivity 
index-2) and pendenticity based descriptor (superpendentic index) were calculated using 
an in-house computer program. The topochemical versions of topostructural descriptors 
were calculated from distance and adjacency matrices weighed by molecular mass with 
respect to that of carbon atom.  
Tab. 2.   Topostructural and topochemical indices 
Code Index  Refe. 
A1  Molecular connectivity topochemical index  35,36 
A2  Eccentric adjacency topochemical index  37 
A3  Augmented eccentric connectivity topochemical index  38 
A4  Superadjacency topochemical index  39 
A5  Eccentric connectivity topochemical index  40 
A6  Connective eccentricity topochemical index  41 
A7  Zagreb topochemical index, M1
C 42 
A8  Zagreb topochemical index, M2
C 42 
A9  Wiener’s topochemical index  43 
A10  Superaugmented eccentric connectivity topochemical index-2   44 
A11  Molecular connectivity index  30 
A12  Eccentric adjacency index  45 
A13  Augmented eccentric connectivity index  46 
A14 Superadjacency  index  39 
A15  Eccentric connectivity index  47 
A16  Connective eccentricity index  48 
A17  Zagreb index, M1 49,50 
A18  Zagreb index, M2 49,50 
A19 Wiener’s  index  51,52 
A20  Superaugmented eccentric connectivity index-2  53 
A21  Balaban mean square distance index  54 
A22 Superpendentic  index  55 
 
Decision tree 
Decision tree provides a useful solution for many problems of classification where large 
datasets are used and the information contained is complex. A decision tree consisting of 
nodes and branches represents a collection of rules with each terminal node 
corresponding to a specific decision rule [56]. Decision trees are constructed beginning 
with the roots of tree and proceeding down to its leaves. In terms of ability, decision trees 
are a rapid and effective method of classifying data set entries and can provide good 
decision support capabilities [57,  58]. Applications of classification-based decision tree 246  M. Gupta, H. Dureja and A. K. Madan:   
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methods predominate in science and medicine [59]. It has been applied to some 
bioinformatics and cheminformatics problems, such as characterizations of tumor [60, 61], 
prediction of drug response [62], classification of antagonist of receptors [63] and 
identification of DNA sections coding exons [64]. 
In present study, decision tree was grown to identify the importance of topological indices. 
In a decision tree, the molecules at each parent node are classified, based upon the index 
value, into two child nodes. The prediction for molecule reaching a given terminal node is 
obtained by majority vote of molecules reaching the same terminal node in the training set. 
In this study, R program (version 2.1.0) along with the RPART library was used to grow 
decision tree. The active compounds were labeled as “A” (n = 9) and the inactive 
compounds were labeled “B” (n = 33). Each analogue was assigned a biological activity 
which was then compared with the reported KDR inhibitory activity [34].  
Moving average analysis 
Moving average analysis of correctly predicted compounds is the basis of development of 
single topological index based model [45, 65]. For the selection and evaluation of range 
specific features, exclusive activity ranges were discovered from the frequency distribution 
of response level and subsequently identify the active range by analyzing the resulting 
data by maximization of the moving average with respect to active compounds (<35% 
inactive, 35–65 % transitional, > 65 % active) The KDR inhibitory activity assigned to each 
compound was compared with reported biological activity. The various ranges obtained 
were also studied for the cKIT and FLT3 inhibitory activities. The average IC50 (nm) for 
each range and activity was also calculated. 
Data analysis 
The sensitivity and specificity values were calculated which represents the classification 
accuracies for the active and inactive compounds, respectively. The randomness of model 
was also predicted by calculating Mathew’s correlation coefficient (MCC). The MCC values 
ranging between −1 to +1 indicates the potential of model. MCC took both sensitivity and 
specificity into account and it is generally used as a balanced measure in dealing with data 
imbalance situation [66]. The intercorrelation between M2
C and Wc, and 
2 c Aξ was also 
investigated. The degree of correlation was appraised by correlation coefficient ‘r’. Pairs of 
indices with r ≥ 0.97 were considered highly inter-correlated, those with 0.90 ≤ r ≤ 0.97 
were appreciably correlated, those with 0.50 ≤ r ≤ 0.89 were weakly correlated and finally 
the pairs of indices with r < 0.50 were not intercorrelated [67]. 
Results and Discussion 
In the present study, decision tree was built from a set of 22 topological indices. The index 
at root node is most important and the importance of index decreases as the length of tree 
increases. The classification of 3-aminoindazoles analogues as inactive and active using a 
single tree, based on Zagreb topochemical index A8 is shown in Fig. 2.  
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Fig. 2.  A decision tree for distinguishing active analogue (A) from inactive analogue 
(B); A8- Zagreb topochemical index, M2
C 
The decision tree identified the Zagreb topochemical index A8 as the most important 
index. The decision tree classified the analogues with an accuracy of 88%. The precision 
and sensitivity of inactive analogues was of the order of 91.11% and 93.93%, whereas the 
precision and sensitivity of active analogues was of the order of 75% and 66.6% 
respectively (Tab. 3). 
Tab. 3.   Confusion matrix for KDR inhibitory activity using models based on decision 
tree  
Number of cpds. predicted 
using decision tree 
Precision 
(%) 
Sensitivity 
(%) 
MCC  Ranges 
Active Inactive       
Active 6  3  75  66.6 
Inactive 2  31  91.11  93.93 
0.63 
 
Three independent moving average analysis (MAA) based topological models were 
developed (Tab. 4.). The topological index A8, Zagreb topochemical index identified as 
most important index by decision tree was used to construct model for the prediction of 
KDR inhibitory activity. Two more indices i.e.  Wiener’s topochemical index, A9 and 
superaugmented eccentric connectivity index-2, A20 were also used to develop the 
models for predicting KDR inhibitory activity. The methodology used in the present study 248  M. Gupta, H. Dureja and A. K. Madan:   
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aims at development of suitable models for providing lead molecules through exploitation 
of the active ranges in the proposed models based on topological indices. Proposed 
models are unique and differ widely from the conventional QSAR models. Both systems of 
modelling have their own advantages and limitations. In the instant case, the modelling 
system adopted has distinct advantage of identification of narrow active range, which may 
be erroneously skipped during routine regression analysis in conventional QSAR 
modelling [44]. Since the ultimate goal of modelling is to provide lead structures, therefore, 
these active ranges can play vital role in lead identification.  
Retrofit analysis of the data reveals the following information with regards to different 
models used in this study. The biological activity was assigned to 42 analogues in both 
active and inactive ranges, out of which activity of 37 analogues was correctly predicted 
resulting in 88.09% accuracy with regard to KDR inhibition using model based on Zagreb 
topochemical index (A8).  
Tab. 4.   MAA based models for the prediction of receptors tyrosine inhibitory activity  
Number of 
analogues 
falling in the 
range 
Model 
Index 
Nature of  
range in 
proposed  
model 
Index  
value 
Total Correct
Overall  
accuracy 
of predict. 
(%) 
KDR 
Aver. 
IC50 
(nM) 
FLT3 
Aver.* 
IC50 
(nM) 
cKIT 
Aver.* 
 IC50 
(nM) 
Lower 
inactive  <139.46 13  12  1379.77  84.54  1629.62  M2
C 
Active  139.46– 
144.63  8 6  9.63  19.86  19.71 
 Upper 
inactive  >144.63 21  19 
88.09 
557.76 189.31  893.14 
Wc Lower 
inactive  <2383.54 16  14  1412.56  80.53  2029.19 
  Active  2383.54– 
2460.04  8 6  9.87  21.29  23.43 
 Upper 
inactive  >2460.04 18  17 
88.09 
391.5 207.86  108.73 
2 c Aξ   Lower 
inactive  <1.62 18  18  389.5  188.36  101.4 
 Active  1.62–1.73  8  6  12.5  25  31 
 Upper 
inactive  >1.73 16  13 
88.09 
1413.5 97  2037.25 
* Average in a range is taken only for the reported IC50 values; 
# Values in brackets are based upon correctly 
predicted analogues in the particular range. 
 
31 out of 34 compounds (91%) in both the inactive ranges were predicted correctly. The 
average IC50 value of all the correctly predicted analogues in both the inactive ranges was 
1494.5 nM and 615.421 nM respectively (Fig. 3). The average IC50 of correctly predicted 
analogues in the active range was found to be only 5 nM with regard to KDR inhibitory 
activity. Such a low average IC50 value signifies high potency of the active range. The said   Models for the Prediction of Receptor Tyrosine Kinase Inhibitory Activity of Substituted …  249 
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active range also exhibited significant FLT3 activity with average IC50 value of 19.86 nM 
(Fig. 4) and cKIT activity with average IC50 value of 19.714 nM (Fig. 5). The precision and 
sensitivity of inactive analogues was found to be 93.93% and 91.11%, whereas the 
precision and sensitivity of active analogues was of the order of 66.6% and 75% 
respectively. The 3-aminoindazoles analogues were correctly classified as active or 
inactive using Wiener’s topochemical index with an accuracy of 88%. The biological 
activity was assigned to 42 analogues in both active and inactive ranges, out of which 37 
analogues were correctly predicted. 31 out of 34 compounds (91.1%) in both the inactive 
ranges were predicted correctly. The average IC50 value of all the correctly predicted 
analogues in both the inactive ranges was 1613.57 nM and 413.94 nM, respectively 
whereas the average IC50 of correctly predicted analogues in the active range was found 
to be only 5.33 nM (Fig. 3). Such a low average IC50 value signifies high potency of the 
active range.  
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Fig. 3.  Average IC50 (nM) values of 3-aminoindazoles for KDR inhibitory activity in 
various ranges of topological models derived through moving average analysis 
The above active range also exhibited significant FLT3 activity with average IC50 value of 
21.29 nM (Fig. 4) and cKIT activity with average IC50 value of 23.43 nM (Fig. 5). 
The precision and sensitivity of inactive analogues was found to be 93.93% and 91.11%, 
whereas the precision and sensitivity of active analogues was of the order of 66.6% and 
75% respectively. 
Superaugmented eccentric connectivity-2, classified the 3-aminoindazoles analogues as 
active and inactive with an accuracy of 88%. The biological activity was assigned to 42 
analogues in both active and inactive ranges, out of which 37 analogues were correctly 
predicted. 31 out of 34 compounds (91.1%) in both the inactive ranges were predicted 
correctly. 
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Fig. 4.   Average IC50 (nM) values of 3-aminoindazoles for FLT3 inhibitory activity in 
various ranges of topological models derived through moving average analysis 
 
The average IC50 value of all the correctly predicted analogues in both the inactive ranges 
was 389.5 nM and 841.75 nM, respectively whereas the average IC50 of correctly 
predicted analogues in the active range was found to be only 6.33 nM (Fig. 3). Such a low 
average IC50 value signifies high potency of the active range. The said active range also 
exhibited significant FLT3 activity with average IC50 value of 25 nM (Fig. 4) and cKIT 
activity with average IC50 value of 31 nM (Fig. 5).  
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Fig. 5.   Average IC50 (nM) values of 3-aminoindazoles for cKIT inhibitory activity in 
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The overall accuracy of prediction was found to be 88%. The precision and sensitivity of 
inactive analogues was found to be 93.93% and 91.11%, whereas the precision and 
sensitivity of active analogues was of the order of 66.6% and 75% respectively. 
Tab. 5.   Intercorrelation matrix 
 M 2
C W c 
2 c Aξ  
M2
C 1 0.92  −0.73
Wc   1  −0.68
2 c Aξ      1 
 
The MCC value was found to be 0.633 (Tab. 3.) suggesting the randomness in the 
distribution of data. The result of intercorrelation analysis (Tab. 5) reveals that the 
2 c Aξ was 
not correlated with M2
C and Wc while the pair M2
C and Wc was found to be appreciably 
correlated 
Conclusion 
Models based on all the three topological descriptors exhibited high degree of predictability 
with regard to KDR inhibitory activity using decision tree and moving average analysis. 
Moreover, the active ranges of the proposed models also exhibited significant FLT3 and 
cKIT inhibitory activities. A combination of VEGFR and PDGFR inhibitory activities will 
naturally be more beneficial for the treatment of tumors. High degree of predictability of the 
proposed models can provide valuable lead structures for the development of potent 
receptor tyrosine kinase inhibitors (RTKs). 
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